作者: Fabian Speth , Johannes-Peter Haas , Claas H. Hinze
DOI: 10.1186/S12969-016-0112-6
关键词:
摘要: Background High-dose intravenous immune globulins (IVIg) are frequently used in refractory juvenile dermatomyositis (JDM) but often poorly tolerated. High-dose recombinant human hyaluronidase-facilitated subcutaneous (fSCIg) allow the administration of much higher doses than conventional globulin therapy and may be an alternative to IVIg. The safety efficacy fSCIg JDM is unknown.